SCOTT RIPLINGER

CGCN GROUP, LLC · Washington, DC · registered since 2024

Registered · LDAActive

Send proposal →Contact →Claim this profile →

At a glance

Registered since

2024

Senate LDA system

Clients

last 3 years

Filings

122

2 agencies contacted

Activity

filings by quarter

Works on

Taxation/Internal Revenue Code 32 Trade (domestic/foreign) 28 Financial Institutions/Investments/Securities 24 Banking 23 Budget/Appropriations 19 Health Issues 14 Energy/Nuclear 13 Labor Issues/Antitrust/Workplace 12 Education 12 Environment/Superfund 12 Computer Industry 11 Science/Technology 10 Fuel/Gas/Oil 10 Homeland Security 10 Consumer Issues/Safety/Products 8 Insurance 8 Defense 8 Housing 8 Disaster Planning/Emergencies 6 Aviation/Airlines/Airports 6 Communications/Broadcasting/Radio/TV 6 Natural Resources 6 Copyright/Patent/Trademark 5 Small Business 5 Manufacturing 5 Clean Air and Water (quality) 5 Telecommunications 4 Transportation 3 Alcohol and Drug Abuse 3 Automotive Industry 3 Foreign Relations 3 Immigration 3 Retirement 3 Tobacco 3 Torts 3 Accounting 3 Law Enforcement/Crime/Criminal Justice 2 Intelligence 2 Economics/Economic Development 2 Chemicals/Chemical Industry 1

Background

Government experience

(4) Legislative Assistant

Rep. Dean Heller, 2007 - 2011; Shared Employee and Staff Assistant, U.S. House Small Business Committee, Rep. Don Manzullo, 2005 - 2007

Disclosed on LD-2 filings

Career

CGCN GROUP, LLC

Washington, DC

2024 - present

Specific issues

Supporting advocacy on hospitality issues.

Small Business · 2024 Q1

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 Naloxone access and awareness legislation State opioid response (SOR) Grant funding for FY25 Substance Abuse and Mental Health Block Grant (SABG) funding and FY25 NDAA for Fiscal Year 2024 and Fiscal Year 2025 - provisions related to biological and chemical defense and access to naloxone HANDS Act - H.R. 5506 SAVE Act of 2023 - H.R. 6161 Overdose Reversal Medication (ORM) Act - H.R. 6243 Workplace Overdose Reversal Kits (WORK) to Save Lives Act - H.R. 5420, S.2948 School Access to Naloxone Act of 2023 - H.R. 3065, S. 2946 Protecting Kids from Fentanyl Act of 2023 - H.R. 4582 Saving Lives in Schools Act of 2023 - H.R. 4240

Homeland Security · 2024 Q3

Domestic law enforcement access to digital evidence generally, and specifically, H.R. 3089 - NDO Fairness Act.

Law Enforcement/Crime/Criminal Justice · 2024 Q3

Issues pertaining to Workforce Development and retraining issues.

Education · 2024 Q3

Issues pertaining to intellectual property rights including, but not limited to, patent protection and enforcement, copyright protection and enforcement in international markets.

Issues pertaining to market access for software products and services in international markets including, but not limited to, provisions related to intellectual property protection and market access for software products and services. Issues pertaining to international trade agreements including, but not limited to, provisions relating to IP protection and enforcement, electronic commerce, services and government procurement.

Trade (domestic/foreign) · 2024 Q3